Cutaneous squamous cell carcinoma in skin of colour

Author: Rajan Ramji, Final-year medical student, University of Auckland, Auckland, New Zealand. DermNet New Zealand Editor in Chief: Hon A/Prof Amanda Oakley, Dermatologist, Hamilton, New Zealand. Copy editor: Maria McGivern. July 2017.


What is cutaneous squamous cell carcinoma?

Cutaneous squamous cell carcinoma (SCC) is a keratinocytic or non-melanoma skin cancer formed by the uncontrolled growth and replication of squamous cells in the epidermis. The keratin produced by these cells is a horny protein that normally forms skin, hair, and nails.

Cutaneous SCCs are invasive into the dermis and may rarely metastasise (spread to other parts of the body). More superficial forms of cutaneous SCC confined within the epidermis are known as intraepidermal SCC or SCC in situ.

Squamous cell carcinoma in white skin

What is skin of colour?

‘Skin of colour’ is a subjective term referring to a natural skin that is ‘darker’ than white (ie, brown or black skin). When compared against a graded assessment of skin colour types, such as the Fitzpatrick phototypes, skin of colour may refer to skin classified as type IV or higher [1]. In some contexts, skin of colour is also used to describe the skin type of different non-white ethnic groups, including those of African, Asian, South American, Pacific Island, Maori, Middle Eastern, and Hispanic descent [2].

Who gets cutaneous squamous cell carcinoma?

Cutaneous SCC is among the most commonly diagnosed cancers worldwide [3].

  • Cutaneous SCC accounts for 15–25% of all diagnosed skin cancers and an estimated 75% of non-melanoma skin cancer-related deaths [3].
  • The highest incidence of cutaneous SCC is seen in white-skinned individuals.
  • Cutaneous SCC is the second most common form of skin cancer seen in Caucasians, Asians, and Hispanics after basal cell carcinoma.
  • It is the most common form of skin cancer seen in blacks and Asian Indians.

Incidence data

The reported incidence rates for cutaneous SCC vary across different studies and time periods; incidence rates per 100,000 population across the last 50 years have included:

  • 0.16–2.9 in Chinese [4,5]
  • 1.4 in Asian Indians [4]
  • 3 in Blacks (estimated) [6]
  • 6 in New Zealand Maori (including basal cell carcinoma) [7].

Compared to skin of colour, cutaneous SCC incidence rates in white skinned people show a significantly stronger correlation with geographic location [8]. For instance, Australia and New Zealand, which share similar latitude, have the highest reported incidence of cutaneous SCC in the world, with reports of 228–1332 and 124–598 cases per 100,000 for Australia and New Zealand respectively in the mid-1990s [3,8]. In comparison, incidence rates in Europe were 9–28.9 per 100,000 [3,8].

Global incidence rates of cutaneous SCC are increasing, especially in white-skinned people [8,9]. Over the last few decades, it has been estimated the cutaneous SCC incidence rate has doubled or tripled across the United States, Australia and Europe [9]. This trend is thought to be related to changes in popular recreational activities and clothing styles, resulting in increased cumulative sun exposure. The majority (~80%) of diagnoses occur in men and women over 60 years of age regardless of skin colour [8]. Men are much more likely than women to develop cutaneous SCC — at double the incidence in some locations [8,9].

Risk factors for cutaneous SCC

Cutaneous SCC is more common in individuals with [10]:

Exposure to ultraviolet (UV) B radiation is a significant risk factor for cutaneous SCC in Caucasians; in skin of colour, scarring may be more significant [3]. There is a 20–40% risk of cutaneous SCC in chronically inflamed, ulcerated, or scarred skin leading to metastasis compared with a 1–4% risk in sun-damaged skin [3].

What causes cutaneous squamous cell carcinoma?

Cutaneous SCC is triggered by an abnormal genetic transformation.

More about mutations to DNA

In white skin, oncogenetic transformation is related to sun exposure, with UVA and UVB radiation damaging and mutating the DNA of these cells [9]. For instance, cutaneous SCC cells have frequently demonstrated mutations to the p53 tumour suppressor gene — a gene that normally functions to repair damaged DNA and prevent the development of tumours [8]. Mutations to this gene may alter its function as p53 mutations are frequently found in many other types of malignancies [8,9]. Similarly, UV exposure can mutate signalling pathways that regulate cell activity such as the epidermal growth factor receptor (EGFR), RAS, Fyn, or p16INK4a pathways. UV radiation may also suppress the ability of the immune system to detect to destroy tumour cells. More significant immunosuppression, such as in transplant patients, may allow infection by human papillomavirus strains implicated in causing cutaneous SCC development [8].

In darker skin, a higher content of UV radiation-absorbing melanin is thought to protect the DNA from mutation and damage.

However, cutaneous SCCs may also arise in areas not exposed to sunlight or outside the skin. As the rates of these cutaneous SCCs can be higher in non-white-skinned ethic groups or display a hereditary pattern, it is thought genetic processes outside of skin pigmentation influence cutaneous SCC development [9]. For instance, even in individuals with the same skin type, variants of the melanocortin 1 receptor (MC1R) gene are believed to increase the risk of cutaneous SCC [9].

What are the clinical features of cutaneous squamous cell carcinoma?

Cutaneous SCCs can occur anywhere on the skin. In white-skinned people, this is typically in areas frequently exposed to the sun [3]. It is estimated that 60–65% of cutaneous SCCs initially arise from actinic keratosis. Others may arise from intraepidermal carcinoma.

In skin of colour, cutaneous SCC more frequently develops in non-sun-exposed areas, such as the legs and feet or in the anogenital region [3]. Cutaneous SCCs:

  • Are typically described as firm, raised nodules or plaques with a crusted or scaly surface [3]
  • Grow over weeks to months
  • May be millimetres to several centimetres in diameter
  • Can be tender
  • May also present as chronic non-healing ulcers [3].

Cutaneous squamous cell carcinoma subtypes

Subtypes of cutaneous SCC include [10]:

Classification of cutaneous squamous cell carcinoma by risk

Cutaneous SCCs can be classified as low or high risk; high-risk features of cutaneous SCC regardless of skin colour include [10]:

  • Arising in older or immunosuppressed individuals
  • Location on the ear, lip, central face, hands, feet, or genitalia
  • Diameter ≥ 2 cm
  • Histological thickness > 2 mm, poorly differentiated histology, or with invasion of the subcutaneous tissue, nerves and blood vessels.

In skin of colour, cutaneous SCCs arising from the perianal region or from scarred skin are high risk due to relatively high metastasis rates [3].

More about risk

Clinicians or pathologists may also define risk by the subtype of SCC. Currently there are no definitive ranking systems used to classify cutaneous SCCs although the following system has been proposed [11]:

  • Low-risk SCC:
    • SCC arising from actinic keratosis
    • HPV-associated SCC
    • Trichilemmal carcinoma
    • Spindle cell SCC not associated with radiation
  • Intermediate-risk SCC:
    • Adenoid (acantholytic) SCC
    • Intraepidermal epithelioma (Borst–Jadassohn) with invasion
    • Lymphoepithelioma-like carcinoma
  • High-risk SCC:
  • Indeterminate-risk SCC:
    • Clear-cell SCC
    • Signet ring cell SCC
    • Papillary SCC
    • Pigmented SCC
    • Follicular SCC
    • SCC derived from adnexal cysts
    • Squamous eccrine ductal carcinoma.

How is cutaneous squamous cell carcinoma diagnosed?

Cutaneous SCCs are usually suspected during a physical examination, often with the aid of a dermatoscope. In skin of colour, special attention may need to be given to areas not typically exposed to the sun and to scarred or inflamed skin [3].

Suspicious lesions are usually surgically removed for pathological examination and treatment (diagnostic excision).

Staging cutaneous SCCs

In patients with high-risk cutaneous SCCs, it may be important to determine the depth of tumour invasion and the spread to surrounding tissue (disease staging). The seventh edition of the American Joint Committee on Cancer (AJCC) staging system for cutaneous SCCs is commonly used [12].

The AJCC tumour staging for cutaneous SCC is as follows [12]:

  • TX: Primary tumour cannot be assessed
  • T0: No evidence of primary tumour
  • Tis: Carcinoma in situ
  • T1: Tumour ≤ 2 cm in greatest dimension with < 2 high-risk features
  • T2: Tumour > 2 cm in greatest dimension with or without one additional high-risk feature, or any size with ≥ 2 high-risk features
  • T3: Tumour with invasion of maxilla, mandible, orbit, or temporal bone
  • T4: Tumour with invasion of skeleton (axial or appendicular) or perineural invasion of skull base.

(High-risk features include depth [> 2-mm thickness; Clark level of dermal invasion ≥ IV]; perineural invasion; location [primary site ear; primary site non-glabrous lip]; and differentiation [poorly differentiated or undifferentiated].)

The AJCC nodal staging for cutaneous SCC is as follows [12]:

  • NX: Regional lymph nodes cannot be assessed
  • N0: No regional lymph node metastasis
  • N1: Metastasis in single ipsilateral lymph node, ≤ 3 cm in greatest dimension
  • N2: Metastasis in single ipsilateral lymph node, > 3 cm but not > 6 cm in greatest dimension; or in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension; or in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension
  • N2a: Metastasis in single ipsilateral lymph node, > 3 cm but not > 6 cm in greatest dimension
  • N2b: Metastasis in multiple ipsilateral lymph nodes, none > 6 cm in greatest dimension
  • N2c: Metastasis in bilateral or contralateral lymph nodes, none > 6 cm in greatest dimension
  • N3: Metastasis in lymph node, > 6 cm in greatest dimension.

The sixth edition of the AJCC staging system classified regional lymph nodes into absence [N0] or presence [N1] of lymph node metastasis; the seventh edition incorporates other prognostic factors, including size, number, and location of regional lymph node metastases.

To determine the stage of cutaneous SCC, the following investigations are usually considered in advanced cases:

  • Ultrasound scans
  • X-rays
  • CT scans
  • MRI scans
  • Regional lymph node examinations
  • Lymph node biopsy
  • Other tissue biopsy. 

What is the differential diagnosis for cutaneous squamous cell carcinoma?

The main lesions that are confused with SCC are:

More about differential diagnosis for cutaneous SCC

Other differential diagnoses for cutaneous SCC include:

Premalignant or malignant lesions:

Benign lesions:

Chronic conditions:

Malignant lesions such as basal cell carcinoma and melanoma have a peak incidence at the same approximate age (60+ years) as cutaneous SCC, and so are more likely to be present simultaneously.

Cutaneous SCCs may occur near or within skin affected by chronic conditions (eg, psoriasis and lichen planus). In these cases, especially where the chronic condition is widespread or poorly controlled, differentiating between lesions can be more difficult.

Compared to white skin, cutaneous SCCs in skin of colour show a more significant association with chronic inflammatory or scarring processes in the skin (Marjolin ulcer) [3].

What is the treatment for cutaneous squamous cell carcinoma?

Surgical excision is the recommended first-line treatment, regardless of skin colour [13]. Recommendations for excision margins are as follows [13]:

  • Low risk, primary cutaneous SCCs less than < 2 cm in diameter are removed with a 4-mm margin of surrounding tissue
  • High risk, cutaneous SCCs > 2 cm are removed with a 6-mm margin of surrounding tissue, especially if they are:
    • Classified as moderately or poorly differentiated
    • Extending into subcutaneous tissues
    • Present on the ear, lip, scalp, eyelid or nose
    • Recurrent.

Other methods of removal include [13]:

Intraepidermal SCCs may be treated with topical creams (fluorouracil or imiquimod) or cryotherapy if surgical removal is unsuitable [13].

  • Currently there is insufficient evidence to determine whether cryotherapy or fluorouracil is a superior treatment [13].
  • Note that the use of imiquimod for intraepidermal SCC is off-licence in New Zealand.

What is the treatment for advanced or metastatic squamous cell carcinoma?

Locally advanced primary, recurrent, or metastatic SCCs require multidisciplinary consultation. A combination of treatments may be used for these aggressive tumours, including:

  • Surgery
  • Radiotherapy
  • Chemotherapy
  • Experimental targeted therapy using epidermal growth factor receptor (EGFR) inhibitors (these are not subsidised in New Zealand for use in cutaneous SCC).

The 2015 European consensus-based interdisciplinary guidelines for locally advanced or metastatic cutaneous SCCs make the recommendations below [14].

  • Surgery should involve the complete removal of the primary cutaneous SCC, in addition to in-transit or satellite metastases.
  • Radiotherapy should be administered, with or without chemotherapy, in cases where surgery is unsuccessful or unfeasible. Radiotherapy may also be used as palliative treatment to limit tumour growth into adjacent areas, provide pain relief, and stop any haemorrhaging.
  • There is no established chemotherapy regimen for cutaneous SCCs. Stage IV (metastatic) cutaneous SCCs have shown remission in response to chemotherapy; however, evidence is limited and the remission is often only observed for a short period of time.
  • EGFR inhibitors may be considered following the failure of chemotherapy, but there is mixed evidence of their effectiveness.

Follow-up for cutaneous squamous cell carcinoma

There are no established guidelines for follow-up. Follow-up is generally recommended given that 30–50% of patients with an SCC are likely to develop another within 5 years [14]. The time between follow-ups is typically based on the risk of new lesions, recurrences or metastases. For patients with a lower risk, an annual follow-up may be sufficient. Patients with a higher risk (eg, renal transplant patients on immunosuppressant medication) may require more closely spaced follow-ups [14].

Cutaneous squamous cell carcinoma prevention in skin of colour

Compared to white-skinned individuals, the association between sun exposure and cutaneous SCC development is less prominent. Regardless, regular self-skin examination or skin checks by a clinician can help identify cutaneous SCCs earlier. It is also still potentially beneficial to minimise sun exposure, given that genetic processes outside skin pigmentation can influence the risk of cutaneous SCC development [9]. Sun protection could involve:

  • Staying indoors or under the shade in the middle of the day
  • Wearing covering clothing
  • Applying high protection factor SPF50+ broad-spectrum topical sunscreens generously to exposed skin if outdoors
  • Avoiding indoor tanning (sun beds and solaria).

In individuals with multiple cutaneous SCCs or individuals at high risk of developing cutaneous SCCs, oral retinoids (ie, acitretin, isotretinoin) may slow tumour growth or the rate of new tumour development [14]. However, these medications often exhibit side effects that while not fatal may prove a nuisance in everyday life (ie, dry skin and mucous membranes). They are also contraindicated in pregnancy due to a high risk of teratogenesis (birth deformities).

What is the outcome for cutaneous squamous cell carcinoma in skin of colour?

Successful treatment of cutaneous SCC is dependent on tumour size and invasion at time of diagnosis. While most SCCs can be cured with treatment, people with skin of colour tend to present with more advanced cutaneous SCCs — especially if they occur on scarred or inflamed skin. As advanced cutaneous SCCs are associated with lower survival rates, treatment outcomes in skin of colour may be poorer [3].

More on prognosis

Cutaneous SCCs > 20 mm in diameter or 2 mm in depth are associated with higher rates of recurrence or mortality. It has been estimated that the 10-year survival rate in patients with cutaneous SCC that has spread to lymph nodes is approximately 20%, and < 10% if distant metastases has occurred [3].

It is currently unknown why people with skin of colour tend to present with more advanced cutaneous SCCs compared to white-skinned individuals. This difference may be due to [3]:

  • Delayed diagnosis
  • Delayed presentation due to misperceptions related to skin cancer susceptibility
  • Tendency for cutaneous SCCs to be more aggressive in areas typically unexposed to sun.

 

Related Information

References

  1. Roberts WE. Skin type classification systems old and new. Dermatol Clin 2009; 27: 529–33. DOI: 10.1016/j.det.2009.08.006. PubMed
  2. Taylor SC. Skin of color: Biology, structure, function, and implications for dermatologic disease. J Am Acad Dermatol 2002; 46 (2 Suppl): S41–62. PubMed
  3. Bradford PT. Skin cancer in skin of color. Dermatology Nurs 2009; 21(4): 170–8. PubMed Central
  4. Kim GK, Del Rosso JQ, Bellew S. Skin cancer in Asians: part 1: nonmelanoma skin cancer. J Clin Aesthet Dermatol 2009; 2(8): 39–42. PubMed Central
  5. Agbai ON, Buster K, Sanchez M, et al. Skin cancer and photoprotection in people of color: a review and recommendations for physicians and the public. J Am Acad Dermatol 2014; 70: 748–62. DOI: 10.1016/j.jaad.2013.11.038. PubMed
  6. Gloster HM, Neal K. Skin cancer in skin of color. J Am Acad Dermatol 2006; 55: 741–60. DOI: 10.1016/j.jaad.2005.08.063. PubMed
  7. Brougham ND, Dennett ER, Tan ST. Non-melanoma skin cancers in New Zealand — a neglected problem. NZ Med J 2010; 123(1325): 59–65. Journal
  8. Leiter U, Eigentler T, Garbe C. Epidemiology of skin cancer. In: Reichrath J (ed.). Sunlight, vitamin D and skin cancer. New York: Springer, 2014: 120–40. ResearchGate
  9. van der Pols J. Epidemiology of basal and squamous cell carcinoma of the skin. In: Dummer R, Pittelkow M, Iwatsuki K, Green A, Elwan N (eds). Skin cancer: a worldwide perspective, 1st edn. Berlin: Springer, 2011: 3–12.
  10. Oakley A. Cutaneous squamous cell carcinoma. DermNet New Zealand. Updated 2015. Available at: www.dermnetnz.org/topics/squamous-cell-carcinoma-of-the-skin (accessed 29 July 2017).
  11. Cassarino DS, DeRienzo DP, Barr RJ. Cutaneous squamous cell carcinoma: a comprehensive clinicopathologic classification. Part One. J Cutan Pathol 2006; 33: 191–206. DOI: 10.1111/j.0303-6987.2006.00516_1.x. PubMed
  12. Farasat S, Yu SS, Neel VA, et al. A new American Joint Committee on Cancer staging system for cutaneous squamous cell carcinoma: creation and rationale for inclusion of tumor (T) characteristics. J Am Acad Dermatol 2011; 64: 1051–9. DOI: 10.1016/j.jaad.2010.08.033. PubMed Central
  13. Motley R, Kersey P, Lawrence C; British Association of Dermatologists. Multiprofessional guidelines for the management of the patient with primary cutaneous squamous cell carcinoma. [Update ofthe original guideline that appeared in Br J Dermatol 2002; 146: 18–25.] 2009. Available at: http://www.bad.org.uk/healthcare-professionals/clinical-standards/clinical-guidelines (accessed 29 July 2017).
  14. Stratigos A, Garbe C, Lebbe C, et al. Diagnosis and treatment of invasive squamous cell carcinoma of the skin: European consensus-based interdisciplinary guideline. Eur J Cancer 2015; 51: 1989–2007. DOI: 10.1016/j.ejca.2015.06.110. Association

On DermNet NZ

Other websites

Books about skin diseases

See the DermNet NZ bookstore.